Published in Vaccine Weekly, January 19th, 2005
This enabling technology is important for the rapid and efficient generation of genetically evolved sublines that exhibit desired phenotypes for uncovering genetic pathways associated with disease as well as discovery and product development.
Dr. Nicholas Nicolaides, president and chief executive officer of Morphotek, commented, "This is yet...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly